CLDXHealthcare · BiotechnologyThe 15 Wall Street analysts covering Celldex Therapeutics, Inc. hold a median 12-month price target of $58 — +51.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 29 of 100 as at 19 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Celldex Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (81): The shares have been drifting up relative to others.
Value (15): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CLDX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +51.7% from it.
Of the 20 most recent actions, 6 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Sept 2026 | Morgan Stanley | Maintains | Overweight | $46 → $50 |
| 7 Aug 2026 | Barclays | Maintains | Overweight | — |
| 7 Aug 2026 | Barclays | Maintains | Overweight | $48 → $53 |
| 7 Aug 2026 | Morgan Stanley | Maintains | Overweight | $40 → $46 |
| 7 Aug 2026 | Morgan Stanley | Maintains | Overweight | — |
| 29 July 2026 | Wells Fargo | Maintains | Overweight | — |
| 29 July 2026 | Wells Fargo | Maintains | Overweight | $48 → $72 |
| 22 July 2026 | Canaccord Genuity | Maintains | Buy | — |
| 22 July 2026 | Canaccord Genuity | Maintains | Buy | $62 → $60 |
| 22 July 2026 | Cantor Fitzgerald | Maintains | Overweight | $67 → $61 |
| 22 July 2026 | Cantor Fitzgerald | Maintains | Overweight | — |
| 22 July 2026 | Morgan Stanley | Maintains | Overweight | $44 → $40 |
| 22 July 2026 | Morgan Stanley | Maintains | Overweight | — |
| 22 July 2026 | Wells Fargo | Maintains | Overweight | $54 → $48 |
| 22 July 2026 | Wells Fargo | Maintains | Overweight | — |
| 20 July 2026 | Guggenheim | Maintains | Buy | — |
| 20 July 2026 | Guggenheim | Maintains | Buy | $90 → $100 |
| 15 June 2026 | HC Wainwright & Co. | Reiterates | Buy | $42 |
| 15 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 June 2026 | UBS | Maintains | Buy | $38 → $45 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CLDX appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 18 Sept 2026, Celldex Therapeutics, Inc. returned +47.5% against +16.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 93% of US stocks
Cheaper than 1% of US stocks
Cheaper than 24% of US stocks
Cheaper than 81% of US stocks
Higher than 2% of US stocks
Higher than 2% of US stocks
Higher than 1% of US stocks
Higher than 30% of US stocks
Higher than 23% of US stocks
Higher than 15% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Celldex Therapeutics, Inc. has a market value of $3.0B and an enterprise value of $2.3B.
Revenue in the twelve months to 30 June 2026: $158K. The latest quarter shrank 97.0% year on year.
Net income over the same four quarters: −$300.5M, a −190220.9% net margin.
Diluted earnings per share, trailing twelve months: $−4.35.
Free cash flow in the twelve months to 30 June 2026: −$242.1M.
Trailing P/E: −9.8×; forward P/E: −9.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Celldex Therapeutics, Inc. employs 198 people — $798.0 of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Celldex Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Celldex announced that management will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference on September 10, 2026 at 8:00am ET.
Why it matters — This indicates an opportunity for investors to hear directly from Celldex management about the company's business at a major healthcare conference.
Purcell & Lefkowitz LLP announced it is investigating Celldex Therapeutics on behalf of shareholders to determine whether the company's directors breached their fiduciary duties in connection with recent corporate actions.
Why it matters — A shareholder investigation into potential director fiduciary breaches introduces legal and governance risk that CLDX watchers will want to monitor.
Celldex Therapeutics reported a second-quarter loss of $0.94 per share, which was narrower than the Zacks Consensus Estimate of a $1.04 loss but wider than the $0.85 per-share loss from a year ago. The company missed revenue estimates for the quarter.
Why it matters — The quarter's results fall short of revenue expectations and show a year-over-year deterioration in per-share losses, which CLDX watchers monitoring the company's financial trajectory would want to track.
Celldex Therapeutics' barzolvolimab phase 3 trials for chronic spontaneous urticaria completed enrollment six months early, with pivotal data expected in September/October 2026 and a potential BLA filing in 2027. The company is also advancing CDX-622, a bispecific TSLP & SCF inhibitor targeting asthma and inflammatory disorders.
Why it matters — The accelerated enrollment timeline for barzolvolimab's phase 3 trials moves Celldex's most advanced candidate closer to a potential regulatory filing, while the early-phase progress of CDX-622 expands the company's pipeline beyond CSU into additional inflammatory indications.
A Zacks Investment Research article compares the year-to-date performance of Celldex Therapeutics (CLDX) to Illumina (ILMN) and their broader medical sector.
Why it matters — CLDX watchers would care because the article offers a relative performance benchmark against both a peer company and the medical sector as a whole.
The 15 Wall Street analysts covering Celldex Therapeutics, Inc. have a median 12-month price target of $58, with estimates ranging from $38 to $100. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 15 analysts covering Celldex Therapeutics, Inc., 14 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Celldex Therapeutics, Inc. 29 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 19 Sept 2026, Celldex Therapeutics, Inc. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (81 of 100).
No one can know that. What the data says: the median 12-month target from 15 analysts implies +51.7% from the last close, and Ticker Nerd's factor model ranks Celldex Therapeutics, Inc. 29 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Celldex Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CLDX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $38 to $100 over the next 12 months.
Celldex Therapeutics, Inc. returned +47.5% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Celldex Therapeutics Inc. is a biopharmaceutical company focused on developing antibody-based therapies for severe inflammatory, allergic, and autoimmune diseases.
The most recent item we track (GlobeNewsWire, 8 Sept 2026): "Celldex to Present at Upcoming Investor Conference". Celldex announced that management will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference on September 10, 2026 at 8:00am ET.
Celldex Therapeutics Inc. is a biopharmaceutical company focused on developing antibody-based therapies for severe inflammatory, allergic, and autoimmune diseases. The company’s current programs center on monoclonal and bispecific antibodies designed to modulate mast cell biology and other immune pathways associated with chronic conditions that have limited treatment options. Its lead clinical assets include barzolvolimab, a KIT-targeting antibody being studied across several mast cell–driven disorders, and CDX-622, a bispecific candidate aimed at key inflammatory mechanisms. Celldex Therapeutics Inc. operates in the biotechnology sector and concentrates on advancing immunology-focused therapies through clinical development for patients with significant unmet medical needs. Headquartered in Hampton, New Jersey, the company is known for its specialized pipeline rather than a broad commercial product portfolio.
CEO Mr. Anthony S. Marucci M.B.A. · 198 employees · United States · https://www.celldex.com
